Elisabet Figuerola Bou
Investigador post-doc
Research group
Research line:
Characterization and relevance of the epigenetic environment in the development of Ewing’s sarcoma
Researcher Elisabet Figuerola Bou graduated in Biomedical Sciences in 2013 from the University of Barcelona and in 2014 she obtained a master's degree in Genetics and Genomics from the same university. In May 2014, she won the first prize for young researchers Gemma Rossell i Romero from the University of Barcelona for her undergraduate work on DNA methylation in cancer in the laboratory of Dr Manel Esteller.
In 2014, she joined Dr Jaume Mora's Developmental Tumors Laboratory at the Sant Joan de Déu Developmental Tumors Laboratory as a predoctoral researcher, where she developed her doctoral dissertation on the role of epigenetics in the development of Ewing's sarcoma. In December 2019 she obtained a PhD in Biomedicine from the University of Barcelona, led by Dr Jaume Mora and Dr Sara Sánchez-Molina. She has also trained in animal experimentation, scientific outreach and bioinformatics analysis for biomedical research.
She is currently working as a postdoctoral researcher in the Sarcomas and Histiocytosis group studying in depth key epigenetic targets for the development and maintenance of Ewing's sarcoma.
Professional network profiles
Last Publications
- Figuerola-Bou E, Rios-Astorch C, Blanco E, Sanchez-Jimenez M, Táboas-Outón P, Fernandez-Isern G, Gomez-Gonzalez S, Muñoz-Aznar O, Castellano P, Pérez-Jaume S, Prada-Varela E, Mateo-Lozano S, Riggi N, Avgustinova A, Lavarino C, Di Croce L, Sánchez-Molina S and Mora J KDM6 demethylases mediate EWSR1-FLI1-driven oncogenic transformation in Ewing Sarcoma Biorxiv . : .
- Sánchez-Molina S, Figuerola-Bou E, Sánchez-Margalet V, de la Cruz-Merino L, Mora J, de Álava Casado E, García-Domínguez DJ and Hontecillas-Prieto L Ewing Sarcoma Meets Epigenetics, Immunology and Nanomedicine: Moving Forward into Novel Therapeutic Strategies Cancers . 14(21): .
- García-Domínguez DJ, Hajji N, López-Alemany R, Sánchez-Molina S, Figuerola-Bou E, Morón Civanto FJ, Rello-Varona S, Andrés-León E, Benito A, Keun HC, Mora J, Tirado ÓM, de Álava E and Hontecillas-Prieto L Selective histone methyltransferase G9a inhibition reduces metastatic development of Ewing sarcoma through the epigenetic regulation of NEU1 Oncogene . 41(18): 2638-2650.
Projects
- Project name:
- SGR 2022-2024_Grup de recerca en tumors del desenvolupament
- Leader
- Jaume Mora Graupera
- Funding entities:
- Agaur - Agència de Gestió d'Ajuts Universitaris i de Recerca
- Code
- 2021 SGR 01612
- Starting - finishing date:
- 2022 - 2025
- Project name:
- Influencia del contexto epigenético en la edad como factor pronóstico en Ewing Sarcoma
- Leader
- Jaume Mora Graupera
- Funding entities:
- Instituto de Salud Carlos III (ISCIII)
- Code
- PI20/00179
- Starting - finishing date:
- 2021 - 2023
- Project name:
- Virtual patient derived xenografts for tumor treatment
- Leader
- Jaume Mora Graupera
- Funding entities:
- Fundació Bancària " La Caixa"
- Code
- HR20-00411
- Starting - finishing date:
- 2020 - 2023
News
-
Describe an epigenetic protein associated with the metastatic process in Ewing's Sarcoma
A study with Dr. Jaume Mora (IRSJD) team participation and led by the Molecular Pathology of Sarcomas group of the Seville Institute of Biomedicine (IBiS) has described that the G9a protein would be associated with the development of metastases in Ewing's Sarcoma. Therefore, the overexpression of this protein would indicate an adverse prognosis.